Nico co-founded Bioqube Ventures in 2015 and serves as Managing Partner. From 2016–2019, he co-managed the JLINX incubation and investment model with Janssen R&D, supporting the creation of 10 biotech ventures and investing in several companies which were successfully exited. In 2020,  Bioqube launched its first independent fund, Bioqube Factory Fund I, with Nico playing a central role.

Before founding Bioqube Ventures, he held senior leadership roles at LRM, where he most recently served as Chief Operating Officer, and gained international experience as a senior executive at Ernst & Young.  He has served on the boards of several public and private life sciences companies and led numerous international venture capital and M&A transactions, including Minerva Neurosciences (Nasdaq: NERV), Tigenix (acquired by Takeda), SEPS Pharma (acquired by Amatsi), and Apitope (acquired by Worg Pharma).

Nico’s drive lies in connecting breakthrough science with capital and entrepreneurship, always with the ambition to enable transformative solutions for patients. His passion and results-driven approach earned him recognition in 2018 as one of Bloomberg50’s “Ones to Watch.”